Literature DB >> 30883635

Prognostic impact of lymphovascular invasion in lymph node-negative superficial esophageal squamous cell carcinoma.

J Oguma1, S Ozawa1, A Kazuno1, M Yamamoto1, Y Ninomiya1, K Yatabe1, H Makuuchi1, G Ogura2.   

Abstract

The relationship between lymphovascular invasion (LVI) and prognosis in patients with superficial esophageal squamous cell carcinoma (SESCC) is unclear. The aim of this study is to evaluate prognostic factors in patients with lymph node-negative SESCC. A total of 195 patients with pathologically confirmed T1a-MM, T1b, and lymph node-negative SESCC were retrospectively reviewed in this study. Overall, the disease-free survival (DFS) rate was poorer in the lymphatic invasion-positive group than in the lymphatic invasion-negative group (p = 0.002) and a multivariate analysis suggested that lymphatic invasion was the only independent prognostic factor of DFS in patients with lymph node-negative SESCC (HR = 4.075, p = 0.005). Distant organ recurrence occurred in one patient (1/52, 1.9%) in the T1b-SM2 group and in six patients (6/61, 9.7%) in the T1b-SM3 group; all of these patients had LVI. LVI-positive patients had a poorer DFS than invasion-negative patients in the T1b-SM2 and SM3 groups (p = 0.026), and a multivariate analysis suggested that LVI was the only independent prognostic factor of DFS in patients with lymph node-negative SM2 and SM3 SESCC (HR = 5.165, p = 0.031). Lymph node-positive patients had a significantly poorer DFS rate than lymph node negative and LVI positive patients among the SM2 and SM3 SESCC patients (p = 0.018). The present results suggested that LVI was an independent prognostic factor in patients with SM2 and SM3 lymph node-negative SESCC; however their prognosis was not worse than that of patients with lymph node-positive SM2 and SM3 SESCC, for whom adjuvant therapy is indicated as a standard treatment.
© The Author(s) 2019. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  lymphovascular invasion; prognostic factor; superficial esophageal squamous cell carcinoma

Mesh:

Year:  2019        PMID: 30883635     DOI: 10.1093/dote/doz001

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  5 in total

1.  Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery.

Authors:  Junya Oguma; Koshiro Ishiyama; Daisuke Kurita; Kyohei Kanematsu; Yusuke Fujii; Kentaro Kubo; Shun Yamamoto; Yoshitaka Honma; Ken Kato; Hiroyuki Daiko
Journal:  Esophagus       Date:  2021-11-10       Impact factor: 4.230

2.  Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma.

Authors:  Junya Oguma; Soji Ozawa; Terue Sakakibara; Hiroshi Kajiwara; Naoya Nakamura; Hiroyasu Makuuchi
Journal:  Ann Gastroenterol Surg       Date:  2020-12-14

3.  The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma.

Authors:  Yu Ma; Xi Yao; Zhenzhen Li; Jie Chen; Wensheng Li; Hongtao Wang; Lanjun Zhang; Jianfei Zhu
Journal:  World J Surg Oncol       Date:  2022-01-10       Impact factor: 2.754

4.  Lymphatic Vessel Invasion in Routine Pathology Reports of Papillary Thyroid Cancer.

Authors:  Costanza Chiapponi; Hakan Alakus; Matthias Schmidt; Michael Faust; Christiane J Bruns; Reinhard Büttner; Marie-Lisa Eich; Anne M Schultheis
Journal:  Front Med (Lausanne)       Date:  2022-02-21

5.  Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma.

Authors:  Yang Li; Meng Yu; Guangda Wang; Li Yang; Chongfei Ma; Mingbo Wang; Meng Yue; Mengdi Cong; Jialiang Ren; Gaofeng Shi
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.